Modality
Cell Therapy
MOA
TYK2i
Target
WRN
Pathway
Notch
PAHT2DMM
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Sep 2029
Phase 1Current
NCT04699747
1,984 pts·PAH
2018-02→2029-09·Terminated
1,984 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-133.5y awayInterim· PAH
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Termina…
Catalysts
Interim
2029-09-13 · 3.5y away
PAH
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04699747 | Phase 1 | PAH | Terminated | 1984 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |